Frangos, Savvas
Iakovou, Ioannis P.
Marlowe, Robert J.
Eftychiou, Nicolaos
Patsali, Loukia
Vanezi, Anna
Savva, Androulla
Mpalaris, Vassilis
Giannoula, Evanthia I.
Article History
Received: 27 June 2016
Accepted: 10 August 2016
First Online: 25 August 2016
Compliance with ethical standards
:
: This was an investigator-initiated study funded from the regular budgets of the Departments of Nuclear Medicine of the participating centres.
: The work of one of the authors (RJM) in developing this paper, including descriptive statistical analysis, organisation and presentation of data, drafting and editing the manuscript, and handling part of manuscript submission logistics, was supported by a grant from Genzyme, a Sanofi company, the manufacturer of recombinant human thyrotropin (Thyrogen). This author is an independent medical editor, whose clients include Genzyme. The other authors declare that they have no conflict of interest.This was a retrospective study, involving no additional procedures. However, all procedures described herein were in accordance with the ethical standards of the institutional and/or national research committees and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required. However, before the radioiodine treatment described herein, written informed consent was obtained from all individual study participants. This consent included allowing use of their data in analyses such as the present study.